nodes	percent_of_prediction	percent_of_DWPC	metapath
Mometasone—Nasal ulcer—Capecitabine—esophageal cancer	0.0809	0.113	CcSEcCtD
Mometasone—Skin depigmentation—Methotrexate—esophageal cancer	0.0682	0.0948	CcSEcCtD
Mometasone—Rosacea—Capecitabine—esophageal cancer	0.0349	0.0486	CcSEcCtD
Mometasone—Telangiectasia—Methotrexate—esophageal cancer	0.0241	0.0335	CcSEcCtD
Mometasone—Amcinonide—ANXA1—esophageal cancer	0.0195	0.27	CrCbGaD
Mometasone—Furunculosis—Methotrexate—esophageal cancer	0.0134	0.0186	CcSEcCtD
Mometasone—Leukoderma—Methotrexate—esophageal cancer	0.0134	0.0186	CcSEcCtD
Mometasone—Impaired healing—Methotrexate—esophageal cancer	0.0131	0.0183	CcSEcCtD
Mometasone—Infection—Carboplatin—esophageal cancer	0.0125	0.0174	CcSEcCtD
Mometasone—Bacterial infection—Methotrexate—esophageal cancer	0.0123	0.0171	CcSEcCtD
Mometasone—Oral candidiasis—Capecitabine—esophageal cancer	0.012	0.0167	CcSEcCtD
Mometasone—Furuncle—Methotrexate—esophageal cancer	0.0116	0.0161	CcSEcCtD
Mometasone—Ulcer—Cisplatin—esophageal cancer	0.0109	0.0152	CcSEcCtD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—KRT17—esophageal cancer	0.0109	0.0519	CbGpPWpGaD
Mometasone—Pain—Carboplatin—esophageal cancer	0.0108	0.015	CcSEcCtD
Mometasone—Haemoptysis—Capecitabine—esophageal cancer	0.0103	0.0143	CcSEcCtD
Mometasone—Wheezing—Cisplatin—esophageal cancer	0.0101	0.014	CcSEcCtD
Mometasone—Body temperature increased—Carboplatin—esophageal cancer	0.00995	0.0138	CcSEcCtD
Mometasone—Otitis media—Capecitabine—esophageal cancer	0.0098	0.0136	CcSEcCtD
Mometasone—Tingling sensation—Capecitabine—esophageal cancer	0.00949	0.0132	CcSEcCtD
Mometasone—Dysphonia—Capecitabine—esophageal cancer	0.00927	0.0129	CcSEcCtD
Mometasone—Folliculitis—Methotrexate—esophageal cancer	0.00904	0.0126	CcSEcCtD
Mometasone—Contusion—Capecitabine—esophageal cancer	0.00874	0.0122	CcSEcCtD
Mometasone—Skin discolouration—Capecitabine—esophageal cancer	0.00845	0.0118	CcSEcCtD
Mometasone—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00838	0.04	CbGpPWpGaD
Mometasone—Nasal congestion—Cisplatin—esophageal cancer	0.00825	0.0115	CcSEcCtD
Mometasone—Hydrocortisone—ANXA1—esophageal cancer	0.0082	0.114	CrCbGaD
Mometasone—Ulcer—Capecitabine—esophageal cancer	0.00807	0.0112	CcSEcCtD
Mometasone—CYP2C8—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00806	0.0385	CbGpPWpGaD
Mometasone—Cataract—Capecitabine—esophageal cancer	0.00801	0.0112	CcSEcCtD
Mometasone—Testolactone—CYP19A1—esophageal cancer	0.00782	0.109	CrCbGaD
Mometasone—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00762	0.0364	CbGpPWpGaD
Mometasone—Influenza like illness—Capecitabine—esophageal cancer	0.00741	0.0103	CcSEcCtD
Mometasone—Candida infection—Capecitabine—esophageal cancer	0.00728	0.0101	CcSEcCtD
Mometasone—NR3C1—Nuclear Receptors—NR1I2—esophageal cancer	0.0068	0.0325	CbGpPWpGaD
Mometasone—Nasopharyngitis—Cisplatin—esophageal cancer	0.00672	0.00935	CcSEcCtD
Mometasone—Ear pain—Capecitabine—esophageal cancer	0.00649	0.00903	CcSEcCtD
Mometasone—Skin discolouration—Methotrexate—esophageal cancer	0.00629	0.00875	CcSEcCtD
Mometasone—Gastroenteritis—Capecitabine—esophageal cancer	0.00625	0.0087	CcSEcCtD
Mometasone—Dexamethasone—ANXA1—esophageal cancer	0.00611	0.0848	CrCbGaD
Mometasone—NR3C1—AP-1 transcription factor network—CRTC1—esophageal cancer	0.00602	0.0287	CbGpPWpGaD
Mometasone—Ulcer—Methotrexate—esophageal cancer	0.006	0.00836	CcSEcCtD
Mometasone—Conjunctivitis—Cisplatin—esophageal cancer	0.00563	0.00783	CcSEcCtD
Mometasone—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALDOB—esophageal cancer	0.00539	0.0257	CbGpPWpGaD
Mometasone—NR3C1—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.00537	0.0257	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—KRT14—esophageal cancer	0.0053	0.0253	CbGpPWpGaD
Mometasone—CYP2C8—Xenobiotics—CYP2A6—esophageal cancer	0.00499	0.0238	CbGpPWpGaD
Mometasone—Nasopharyngitis—Capecitabine—esophageal cancer	0.00495	0.00689	CcSEcCtD
Mometasone—CYP2C8—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.0048	0.0229	CbGpPWpGaD
Mometasone—Influenza—Capecitabine—esophageal cancer	0.00479	0.00666	CcSEcCtD
Mometasone—Asthma—Capecitabine—esophageal cancer	0.00479	0.00666	CcSEcCtD
Mometasone—Bronchospasm—Capecitabine—esophageal cancer	0.00471	0.00655	CcSEcCtD
Mometasone—Immune system disorder—Cisplatin—esophageal cancer	0.00469	0.00653	CcSEcCtD
Mometasone—Mediastinal disorder—Cisplatin—esophageal cancer	0.00468	0.00652	CcSEcCtD
Mometasone—Bronchitis—Capecitabine—esophageal cancer	0.0046	0.00641	CcSEcCtD
Mometasone—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00445	0.00619	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—esophageal cancer	0.00437	0.0208	CbGpPWpGaD
Mometasone—Urinary tract infection—Capecitabine—esophageal cancer	0.00415	0.00577	CcSEcCtD
Mometasone—Conjunctivitis—Capecitabine—esophageal cancer	0.00415	0.00577	CcSEcCtD
Mometasone—Epistaxis—Capecitabine—esophageal cancer	0.00403	0.0056	CcSEcCtD
Mometasone—CYP2C8—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00387	0.0185	CbGpPWpGaD
Mometasone—Myalgia—Cisplatin—esophageal cancer	0.00385	0.00536	CcSEcCtD
Mometasone—Rhinitis—Capecitabine—esophageal cancer	0.00384	0.00535	CcSEcCtD
Mometasone—Pharyngitis—Capecitabine—esophageal cancer	0.0038	0.00529	CcSEcCtD
Mometasone—Anaphylactic shock—Cisplatin—esophageal cancer	0.00369	0.00514	CcSEcCtD
Mometasone—Infection—Cisplatin—esophageal cancer	0.00367	0.00511	CcSEcCtD
Mometasone—Asthma—Methotrexate—esophageal cancer	0.00356	0.00496	CcSEcCtD
Mometasone—NR3C1—Endoderm Differentiation—SOX2—esophageal cancer	0.00354	0.0169	CbGpPWpGaD
Mometasone—Anorexia—Cisplatin—esophageal cancer	0.00352	0.0049	CcSEcCtD
Mometasone—Immune system disorder—Capecitabine—esophageal cancer	0.00346	0.00482	CcSEcCtD
Mometasone—Mediastinal disorder—Capecitabine—esophageal cancer	0.00345	0.00481	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—esophageal cancer	0.00345	0.0165	CbGpPWpGaD
Mometasone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00336	0.00468	CcSEcCtD
Mometasone—Paraesthesia—Cisplatin—esophageal cancer	0.00332	0.00461	CcSEcCtD
Mometasone—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00331	0.00461	CcSEcCtD
Mometasone—Dyspnoea—Cisplatin—esophageal cancer	0.00329	0.00458	CcSEcCtD
Mometasone—Prednisolone—CYP2A6—esophageal cancer	0.00329	0.0457	CrCbGaD
Mometasone—CYP2C8—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00328	0.0157	CbGpPWpGaD
Mometasone—Back pain—Capecitabine—esophageal cancer	0.00323	0.00449	CcSEcCtD
Mometasone—Decreased appetite—Cisplatin—esophageal cancer	0.00321	0.00447	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00317	0.0151	CbGpPWpGaD
Mometasone—Pain—Cisplatin—esophageal cancer	0.00316	0.00439	CcSEcCtD
Mometasone—Conjunctivitis—Methotrexate—esophageal cancer	0.00309	0.0043	CcSEcCtD
Mometasone—Betamethasone—CYP19A1—esophageal cancer	0.00307	0.0426	CrCbGaD
Mometasone—Epistaxis—Methotrexate—esophageal cancer	0.003	0.00417	CcSEcCtD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—SFN—esophageal cancer	0.00295	0.0141	CbGpPWpGaD
Mometasone—Body temperature increased—Cisplatin—esophageal cancer	0.00292	0.00406	CcSEcCtD
Mometasone—Cough—Capecitabine—esophageal cancer	0.00291	0.00405	CcSEcCtD
Mometasone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00291	0.0139	CbGpPWpGaD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00289	0.0138	CbGpPWpGaD
Mometasone—CYP2C8—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00287	0.0137	CbGpPWpGaD
Mometasone—Dexamethasone—NOS2—esophageal cancer	0.00286	0.0397	CrCbGaD
Mometasone—Myalgia—Capecitabine—esophageal cancer	0.00284	0.00395	CcSEcCtD
Mometasone—Chest pain—Capecitabine—esophageal cancer	0.00284	0.00395	CcSEcCtD
Mometasone—Arthralgia—Capecitabine—esophageal cancer	0.00284	0.00395	CcSEcCtD
Mometasone—Pharyngitis—Methotrexate—esophageal cancer	0.00283	0.00394	CcSEcCtD
Mometasone—Dry mouth—Capecitabine—esophageal cancer	0.00278	0.00386	CcSEcCtD
Mometasone—Infection—Capecitabine—esophageal cancer	0.0027	0.00376	CcSEcCtD
Mometasone—Asthenia—Cisplatin—esophageal cancer	0.00265	0.00369	CcSEcCtD
Mometasone—Anorexia—Capecitabine—esophageal cancer	0.00259	0.00361	CcSEcCtD
Mometasone—Immune system disorder—Methotrexate—esophageal cancer	0.00258	0.00359	CcSEcCtD
Mometasone—Mediastinal disorder—Methotrexate—esophageal cancer	0.00257	0.00358	CcSEcCtD
Mometasone—NR3C1—Adipogenesis—CYP26A1—esophageal cancer	0.00254	0.0121	CbGpPWpGaD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00254	0.0121	CbGpPWpGaD
Mometasone—Diarrhoea—Cisplatin—esophageal cancer	0.00253	0.00352	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00248	0.00345	CcSEcCtD
Mometasone—Paraesthesia—Capecitabine—esophageal cancer	0.00244	0.0034	CcSEcCtD
Mometasone—Dexamethasone—CYP1B1—esophageal cancer	0.00243	0.0338	CrCbGaD
Mometasone—Dyspnoea—Capecitabine—esophageal cancer	0.00243	0.00338	CcSEcCtD
Mometasone—Back pain—Methotrexate—esophageal cancer	0.0024	0.00334	CcSEcCtD
Mometasone—Dyspepsia—Capecitabine—esophageal cancer	0.0024	0.00333	CcSEcCtD
Mometasone—Decreased appetite—Capecitabine—esophageal cancer	0.00237	0.00329	CcSEcCtD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00236	0.0113	CbGpPWpGaD
Mometasone—Vomiting—Cisplatin—esophageal cancer	0.00235	0.00327	CcSEcCtD
Mometasone—Fatigue—Capecitabine—esophageal cancer	0.00235	0.00327	CcSEcCtD
Mometasone—Rash—Cisplatin—esophageal cancer	0.00233	0.00324	CcSEcCtD
Mometasone—Pain—Capecitabine—esophageal cancer	0.00233	0.00324	CcSEcCtD
Mometasone—Dermatitis—Cisplatin—esophageal cancer	0.00233	0.00324	CcSEcCtD
Mometasone—CYP2C8—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00227	0.0109	CbGpPWpGaD
Mometasone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00223	0.0031	CcSEcCtD
Mometasone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—esophageal cancer	0.0022	0.0105	CbGpPWpGaD
Mometasone—Nausea—Cisplatin—esophageal cancer	0.00219	0.00305	CcSEcCtD
Mometasone—Fluticasone furoate—ABCB1—esophageal cancer	0.00218	0.0302	CrCbGaD
Mometasone—Cough—Methotrexate—esophageal cancer	0.00217	0.00302	CcSEcCtD
Mometasone—Abdominal pain—Capecitabine—esophageal cancer	0.00215	0.00299	CcSEcCtD
Mometasone—Body temperature increased—Capecitabine—esophageal cancer	0.00215	0.00299	CcSEcCtD
Mometasone—Myalgia—Methotrexate—esophageal cancer	0.00211	0.00294	CcSEcCtD
Mometasone—Chest pain—Methotrexate—esophageal cancer	0.00211	0.00294	CcSEcCtD
Mometasone—Arthralgia—Methotrexate—esophageal cancer	0.00211	0.00294	CcSEcCtD
Mometasone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00207	0.0099	CbGpPWpGaD
Mometasone—CYP2C8—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00205	0.00977	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00204	0.00976	CbGpPWpGaD
Mometasone—Anaphylactic shock—Methotrexate—esophageal cancer	0.00203	0.00282	CcSEcCtD
Mometasone—NR3C1—Endoderm Differentiation—SMAD4—esophageal cancer	0.00202	0.00964	CbGpPWpGaD
Mometasone—Infection—Methotrexate—esophageal cancer	0.00201	0.0028	CcSEcCtD
Mometasone—NR3C1—Circadian Clock—HIF1A—esophageal cancer	0.00196	0.00935	CbGpPWpGaD
Mometasone—Asthenia—Capecitabine—esophageal cancer	0.00195	0.00272	CcSEcCtD
Mometasone—CYP2C8—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00193	0.00924	CbGpPWpGaD
Mometasone—Anorexia—Methotrexate—esophageal cancer	0.00193	0.00269	CcSEcCtD
Mometasone—Pruritus—Capecitabine—esophageal cancer	0.00193	0.00268	CcSEcCtD
Mometasone—Dexamethasone—ABCC2—esophageal cancer	0.0019	0.0263	CrCbGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00189	0.009	CbGpPWpGaD
Mometasone—Dexamethasone—CYP2A6—esophageal cancer	0.00188	0.026	CrCbGaD
Mometasone—Diarrhoea—Capecitabine—esophageal cancer	0.00186	0.00259	CcSEcCtD
Mometasone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00185	0.00257	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00182	0.0087	CbGpPWpGaD
Mometasone—Paraesthesia—Methotrexate—esophageal cancer	0.00182	0.00253	CcSEcCtD
Mometasone—Dyspnoea—Methotrexate—esophageal cancer	0.00181	0.00251	CcSEcCtD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00179	0.00854	CbGpPWpGaD
Mometasone—Dexamethasone—CYP19A1—esophageal cancer	0.00179	0.0248	CrCbGaD
Mometasone—Dyspepsia—Methotrexate—esophageal cancer	0.00178	0.00248	CcSEcCtD
Mometasone—Decreased appetite—Methotrexate—esophageal cancer	0.00176	0.00245	CcSEcCtD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD4—esophageal cancer	0.00176	0.00838	CbGpPWpGaD
Mometasone—Fatigue—Methotrexate—esophageal cancer	0.00175	0.00243	CcSEcCtD
Mometasone—Methylprednisolone—ABCB1—esophageal cancer	0.00174	0.0241	CrCbGaD
Mometasone—Pain—Methotrexate—esophageal cancer	0.00173	0.00241	CcSEcCtD
Mometasone—Vomiting—Capecitabine—esophageal cancer	0.00173	0.00241	CcSEcCtD
Mometasone—Triamcinolone—PTGS2—esophageal cancer	0.00172	0.0239	CrCbGaD
Mometasone—Rash—Capecitabine—esophageal cancer	0.00172	0.00239	CcSEcCtD
Mometasone—Dermatitis—Capecitabine—esophageal cancer	0.00171	0.00239	CcSEcCtD
Mometasone—Headache—Capecitabine—esophageal cancer	0.00171	0.00237	CcSEcCtD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00168	0.00803	CbGpPWpGaD
Mometasone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00167	0.00798	CbGpPWpGaD
Mometasone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00166	0.00231	CcSEcCtD
Mometasone—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00165	0.00788	CbGpPWpGaD
Mometasone—NR3C1—Regulation of Androgen receptor activity—CREBBP—esophageal cancer	0.00165	0.00787	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—BAX—esophageal cancer	0.00164	0.00785	CbGpPWpGaD
Mometasone—Nausea—Capecitabine—esophageal cancer	0.00162	0.00225	CcSEcCtD
Mometasone—NR3C1—AP-1 transcription factor network—HIF1A—esophageal cancer	0.00161	0.00771	CbGpPWpGaD
Mometasone—Body temperature increased—Methotrexate—esophageal cancer	0.0016	0.00223	CcSEcCtD
Mometasone—Abdominal pain—Methotrexate—esophageal cancer	0.0016	0.00223	CcSEcCtD
Mometasone—NR3C1—Circadian Clock—CREBBP—esophageal cancer	0.0016	0.00764	CbGpPWpGaD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00159	0.00761	CbGpPWpGaD
Mometasone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00157	0.0075	CbGpPWpGaD
Mometasone—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00155	0.00741	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—ADH7—esophageal cancer	0.00154	0.00734	CbGpPWpGaD
Mometasone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—esophageal cancer	0.0015	0.00714	CbGpPWpGaD
Mometasone—NR3C1—Endoderm Differentiation—NOTCH1—esophageal cancer	0.00149	0.00711	CbGpPWpGaD
Mometasone—Asthenia—Methotrexate—esophageal cancer	0.00145	0.00202	CcSEcCtD
Mometasone—Pruritus—Methotrexate—esophageal cancer	0.00143	0.002	CcSEcCtD
Mometasone—NR3C1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00142	0.00676	CbGpPWpGaD
Mometasone—Betamethasone—PTGS2—esophageal cancer	0.00141	0.0196	CrCbGaD
Mometasone—Diarrhoea—Methotrexate—esophageal cancer	0.00139	0.00193	CcSEcCtD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00135	0.00647	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—ADH1B—esophageal cancer	0.00135	0.00644	CbGpPWpGaD
Mometasone—Prednisone—ABCB1—esophageal cancer	0.00133	0.0184	CrCbGaD
Mometasone—Vomiting—Methotrexate—esophageal cancer	0.00129	0.00179	CcSEcCtD
Mometasone—Rash—Methotrexate—esophageal cancer	0.00128	0.00178	CcSEcCtD
Mometasone—Dermatitis—Methotrexate—esophageal cancer	0.00128	0.00178	CcSEcCtD
Mometasone—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00127	0.00608	CbGpPWpGaD
Mometasone—Headache—Methotrexate—esophageal cancer	0.00127	0.00177	CcSEcCtD
Mometasone—CYP2C8—Biological oxidations—CYP26A1—esophageal cancer	0.00125	0.00598	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00124	0.0059	CbGpPWpGaD
Mometasone—Prednisolone—ABCB1—esophageal cancer	0.00123	0.017	CrCbGaD
Mometasone—Nausea—Methotrexate—esophageal cancer	0.0012	0.00167	CcSEcCtD
Mometasone—Betamethasone—ABCB1—esophageal cancer	0.0012	0.0167	CrCbGaD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—esophageal cancer	0.00117	0.0056	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—GSTO1—esophageal cancer	0.00116	0.00556	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—esophageal cancer	0.00116	0.00555	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—CDKN2A—esophageal cancer	0.00115	0.00552	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—GSTO1—esophageal cancer	0.00115	0.00549	CbGpPWpGaD
Mometasone—NR3C1—Regulation of Androgen receptor activity—EP300—esophageal cancer	0.00112	0.00536	CbGpPWpGaD
Mometasone—NR3C1—Circadian Clock—EP300—esophageal cancer	0.00109	0.0052	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—HIF1A—esophageal cancer	0.000984	0.0047	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—CCND1—esophageal cancer	0.000976	0.00466	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—ALDH2—esophageal cancer	0.00095	0.00454	CbGpPWpGaD
Mometasone—Hydrocortisone—ABCB1—esophageal cancer	0.000937	0.013	CrCbGaD
Mometasone—NR3C1—Generic Transcription Pathway—NR1I2—esophageal cancer	0.000928	0.00443	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—GSTT1—esophageal cancer	0.000903	0.00431	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—EP300—esophageal cancer	0.000898	0.00429	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—CYP2A6—esophageal cancer	0.000893	0.00426	CbGpPWpGaD
Mometasone—CYP2C8—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000872	0.00416	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00085	0.00406	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—PTGS1—esophageal cancer	0.000846	0.00404	CbGpPWpGaD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.00084	0.00401	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—esophageal cancer	0.000832	0.00397	CbGpPWpGaD
Mometasone—Dexamethasone—PTGS2—esophageal cancer	0.000821	0.0114	CrCbGaD
Mometasone—NR3C1—Adipogenesis—RB1—esophageal cancer	0.000801	0.00382	CbGpPWpGaD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.000799	0.00382	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—EP300—esophageal cancer	0.000791	0.00378	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—MYC—esophageal cancer	0.000783	0.00374	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—CYP1B1—esophageal cancer	0.00072	0.00344	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00071	0.00339	CbGpPWpGaD
Mometasone—Dexamethasone—ABCB1—esophageal cancer	0.000698	0.00969	CrCbGaD
Mometasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000696	0.00333	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000695	0.00332	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000694	0.00332	CbGpPWpGaD
Mometasone—CYP2C8—Biological oxidations—CYP19A1—esophageal cancer	0.000677	0.00323	CbGpPWpGaD
Mometasone—CYP2C8—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000667	0.00319	CbGpPWpGaD
Mometasone—NR3C1—AP-1 transcription factor network—TP53—esophageal cancer	0.000643	0.00307	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—SMG6—esophageal cancer	0.00059	0.00282	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000583	0.00278	CbGpPWpGaD
Mometasone—NR3C1—Adipogenesis—CDKN1A—esophageal cancer	0.000575	0.00275	CbGpPWpGaD
Mometasone—NR3C1—Glucocorticoid receptor regulatory network—TP53—esophageal cancer	0.000566	0.0027	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000523	0.0025	CbGpPWpGaD
Mometasone—NR3C1—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000473	0.00226	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000469	0.00224	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—NR1I2—esophageal cancer	0.000447	0.00213	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000439	0.0021	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000409	0.00195	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—HIST1H2BM—esophageal cancer	0.000383	0.00183	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.000364	0.00174	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.000364	0.00174	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000325	0.00155	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000324	0.00155	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CA1—esophageal cancer	0.000309	0.00148	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—SLC10A2—esophageal cancer	0.000309	0.00148	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—PSME1—esophageal cancer	0.000297	0.00142	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—PSME2—esophageal cancer	0.000297	0.00142	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000293	0.0014	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CA2—esophageal cancer	0.000283	0.00135	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—NOTCH3—esophageal cancer	0.000281	0.00134	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000276	0.00132	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PLCE1—esophageal cancer	0.000263	0.00126	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ADH7—esophageal cancer	0.000263	0.00126	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.00026	0.00124	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—NOTCH2—esophageal cancer	0.000252	0.0012	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ADH1B—esophageal cancer	0.000231	0.0011	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—TYMP—esophageal cancer	0.00022	0.00105	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CYP26A1—esophageal cancer	0.000214	0.00102	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—SMAD4—esophageal cancer	0.000211	0.00101	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ALOX15—esophageal cancer	0.000209	0.000997	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GSTO1—esophageal cancer	0.000199	0.000951	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—TPI1—esophageal cancer	0.000199	0.000951	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ALDOB—esophageal cancer	0.000191	0.000912	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GAPDH—esophageal cancer	0.000184	0.000878	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CRABP1—esophageal cancer	0.000182	0.00087	CbGpPWpGaD
Mometasone—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	0.000174	0.000832	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GNG7—esophageal cancer	0.000173	0.000828	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ALDH2—esophageal cancer	0.000162	0.000776	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—NOTCH1—esophageal cancer	0.000156	0.000744	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—GSTT1—esophageal cancer	0.000154	0.000738	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CYP2A6—esophageal cancer	0.000153	0.000729	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000152	0.000726	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ENO1—esophageal cancer	0.000145	0.000691	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PTGS1—esophageal cancer	0.000145	0.000691	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PSME1—esophageal cancer	0.000143	0.000681	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PSME2—esophageal cancer	0.000143	0.000681	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—CREBBP—esophageal cancer	0.000141	0.000675	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000125	0.000595	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CYP1B1—esophageal cancer	0.000123	0.000588	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CYP19A1—esophageal cancer	0.000116	0.000553	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—HMOX1—esophageal cancer	0.000106	0.000504	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000104	0.000495	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—ABCB1—esophageal cancer	0.000101	0.000484	CbGpPWpGaD
Mometasone—NR3C1—Gene Expression—MYC—esophageal cancer	8.38e-05	0.0004	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.66e-05	0.000366	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—CREBBP—esophageal cancer	6.77e-05	0.000324	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—NOS3—esophageal cancer	6.06e-05	0.00029	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PTGS2—esophageal cancer	5.55e-05	0.000265	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—EP300—esophageal cancer	4.61e-05	0.00022	CbGpPWpGaD
Mometasone—CYP2C8—Metabolism—PIK3CA—esophageal cancer	3.41e-05	0.000163	CbGpPWpGaD
